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ABSTRACT
Alternative pre-mRNA processing is a central
element of eukaryotic gene regulation. The cell
frequently alters the use of alternative exons in
response to physiological stimuli. Ceramides are
lipid-signaling molecules composed of sphingosine
and a fatty acid. Previously, water-insoluble cera-
mides were shown to change alternative splicing
and decrease SR-protein phosphorylation by
activating protein phosphatase-1 (PP1). To gain
further mechanistical insight into ceramide-
mediated alternative splicing, we analyzed the effect
of C6 pyridinium ceramide (PyrCer) on alternative
splice site selection. PyrCer is a water-soluble
ceramide analog that is under investigation as a
cancer drug. We found that PyrCer binds to the PP1
catalytic subunit and inhibits the dephosphorylation
of several splicing regulatory proteins containing the
evolutionarily conserved RVxF PP1-binding motif
(including PSF/SFPQ, Tra2-beta1 and SF2/ASF). In
contrast to natural ceramides, PyrCer promotes
phosphorylation of splicing factors. Exons that are
regulated by PyrCer have in common suboptimal
splice sites, are unusually short and share two 4-nt
motifs, GAAR and CAAG. They are dependent on
PSF/SFPQ, whose phosphorylation is regulated by
PyrCer. Our results indicate that lipids can influence
pre-mRNA processing by regulating the phosphoryl-
ation status of specific regulatory factors, which is
mediated by protein phosphatase activity.
INTRODUCTION
All polymerase-II transcripts undergo pre-mRNA
processing and at least 95% of the transcriptional units
are alternatively spliced (1). The exact regulation of alter-
native splicing events is physiologically important, as
evidenced by an increasing number of diseases that are
caused by the selection of the wrong splice site (2). The
proper recognition of exons is regulated by the transient
formation of protein complexes on the pre-mRNA that
identify a sequence for its recognition by the spliceosome.
The signals on the pre-mRNA that mark an exon for its
inclusion in the mRNA are highly degenerate, most likely
to avoid interference with coding requirements. Therefore,
exons are recognized by the formation of a complex
between the pre-mRNA and various hnRNPs and SR
proteins. Since these proteins generally bind to RNA
with low selectivity, a higher speciﬁcity is achieved by
simultaneous binding of the proteins to each other.
The interaction between these proteins is regulated in
part by their phosphorylation status. For example,
protein phosphatase-1 (PP1)-mediated dephosphorylation
promotes the interaction between Tra2-beta1 and
SF2/ASF (also called SRSF1) in vitro (3). Reversible phos-
phorylation of SR proteins and hnRNPs is achieved by an
interplay between protein kinases and phosphatases.
Several SR proteins contain an evolutionarily highly
conserved PP1 binding element (RVxF) in their
RNA recognition motif which allows PP1 to inﬂuence
the phosphorylation status of proteins bound to pre-
mRNA. In addition to the interaction between individual
SR proteins, the afﬁnity between components of the
spliceosome, such as U1-70K and proteins that associate
with pre-mRNA, including PSF/SFPQ (4), SRp38 (5) and
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This suggests that PP1 activity can regulate the recogni-
tion of pre-mRNA substrates by the spliceosome and
inﬂuences the selection of alternative exons by altering
protein afﬁnities. In agreement with this model, a
change in PP1 activity has been shown to alter splice site
selection in vivo (3,7,8).
Ceramides are a class of sphingolipids that are
composed of sphingosine and a fatty acid moiety. In the
cell, ceramide can be generated by sphyingomyelin
hydrolysis by sphingomyelinase or by de novo synthesis.
Sphingomyelin and sphingomyelinase are both present in
the nucleus, which led to the suggestion that they partici-
pate in nuclear signaling (9). Natural ceramides contain
long alkyl groups (C14–26) and are therefore hydropho-
bic. It has previously been shown that endogenous
ceramides alter bcl-x splicing via a purine-rich splicing
enhancer (10). To improve delivery and water solubility,
cationic-ceramide analogs containing pyridinium moieties
were synthesized. Owing to their ability to induce apop-
tosis, these water-soluble ceramide analogs have been
tested as anti-cancer drugs (11,12). Despite their usage in
clinical studies, the effect of these pyridinium ceramides on
alternative splicing has not been determined.
Here, we investigate the role of a water-soluble
ceramide analog, C6 pyridinium ceramide (PyrCer), in
alternative splicing. We found that PyrCer treatment
inhibits the dephosphorylation of splicing regulatory
proteins by PP1, which is opposite to the activation
reported for water-insoluble short and long-chain
ceramides (13). In addition to SR proteins known to be
affected by natural ceramides, PyrCer treatment increases
the phosphorylation of other proteins involved in splicing,
such as PSF/SFPQ, SAP155 and UAP56. It changes the
alternative splicing patterns of exons that are short and
dependent on splicing enhancers. These ﬁndings suggest
that the dephosphorylation of splicing factors by PP1 is
a molecular link between lipids and alternative splice site
selection. The difference between PyrCer and natural
ceramides suggest that subclasses of lipids have distincitve
effects on splice site selection.
MATERIALS AND METHODS
Cell culture and transfection
HEK 293T cells were grown in DMEM (Invitrogen)
supplemented with 10% (v/v) fetal bovine serum
(Invitrogen) for 24h to 80% conﬂuence prior to ceramide
treatment and to 60–70% conﬂuence prior to calcium
phosphate transfections. Transfection of the minigenes
and RT-PCR analyses was performed as described (14).
Ceramide treatment
Four microliters of HeLa nuclear extract (Dundee Cell
Products) was incubated in 1mM MnCl2 and 1  PNK
buffer (70mM Tris–HCl pH 7.6, 10mM MgCl2,5 m M
dithiothreitol). Twenty micromolar of C6 pyridinium
ceramide (D-erythro-2-N-[60-(1-pyridinium)-hexanoyl]-
sphingosine bromide) (Avanti Polar Lipids), or 20mM
1-(2-oxopropyl) pyridinium bromide (Sigma-Aldrich)
was added. After 5min at 37 C, 4mCi of [g-
32P] ATP
(7000Ci/mmol, MP Biochemical) was added. The 50ml
reactions were then incubated for 30min and the
reaction was stopped by adding 6  SDS sample buffer
(0.375M Tris–HCl pH 6.8, 30% glycerol, 12% SDS,
12% 2-b mercaptoethanol and 0.075% bromophenol
blue) followed by 10% SDS–PAGE. Proteins that were
differentially phosphorylated in the ceramide lanes were
excised from the gel and analyzed by MALDI TOF/TOF.
Minigene construction
Minigenes were constructed as described (14). The primers
for the minigenes and the insert sequences are shown in
Supplementary Figure S1.
Phosphatase assays
Hydrolysis of p-nitrophenylphosphate (p-NPP) was
performed in 25ml reactions containing 1  phosphate
buffer (0.1M sodium acetate, 0.05M bis–Tris, 0.05M
Tris–HCl, 2mM dithiothreitol, at pH 8.0), 50mM
pNPP, 1mM MnCl2 and 0.1U of puriﬁed PP1 enzyme
mix (Upstate, #14-110) at 37 C for 30min. A PP1 unit
releases 1nmol of phosphate/min from 15mM phosphor-
ylase at 30 C. The reaction was terminated by the addition
of 100ml of 0.25M NaOH and absorbance was measured
at 410nm. The activity of PP1 on Phosphorylase b was
measured as previously described (15).
C6 pyridinium ceramide treatment of HeLa nuclear
extracts
Ten micrograms of HeLa nuclear extract (NE) was
incubated with 4mCi [g
32P] ATP for 30min at 37 C
in 1  PNK buffer (New England Bio Labs) plus or
10mM C6 pyridinium ceramide in a 50ml ﬁnal volume.
Radiolabeled-NE proteins were then subjected to
immunoprecipitation overnight with 2mg of indicated
antibodies, 10ml proteins A/G beads (Santa Cruz) and
200ml RIPA-rescue buffer containing phosphatase and
protease inhibitors. Immunoprecipitates were subjected
to SDS–PAGE, proteins were transferred on to nitrocel-
lulose membranes and analyzed by phosphor-imaging.
The membranes were then blotted with the indicated
antibodies for total protein expression. Representative
32P signals and western blot results of triplicate experi-
ments for SF2/ASF, Tra2-beta1, PSF, UAP56 and
SAP155 are shown.
Protein expression and puriﬁcation
Recombinant proteins were overexpressed in Escherichia
coli BL21 (DE3) cells. Expression was induced with IPTG
in a ﬁnal concentration of 0.4mM for 4h at room tem-
perature. The His-Tra2-beta1 protein and His-PSF
protein were puriﬁed under denaturing conditions on
Ni-NTA resin (QIAGEN). The cells were lysed in buffer
#1 [20mM Tris, 300mM NaCl, 100mM MOPS, 15%
glycerol and 4M guanidine hydrochloride pH (7.5)]
using a French press. The cell lysate was clariﬁed by cen-
trifugation at 10000 g for 30min at 4 C. The super-
natant was incubated with Ni-NTA resin for 1h at room
4026 Nucleic Acids Research, 2012,Vol.40, No. 9temperature. The resin was poured into a column and
washed with buffer #1 containing 20mM imidazole
followed by washing steps with refolding buffers [buffer
#1 containing decreasing concentration of GuHCl (pH
6.5)]. The proteins were eluted using buffer #5 [20mM
Tris–HCl, 300mM NaCl, 100mM MOPS, 15% glycerol
(pH 2.2)].
GST-tagged SF2/ASF transformed E. coli cells were
lysed in buffer A [50mM Tris–HCl (pH 7.5), 300mM
NaCl, 0.5% Triton X-100, 0.1% 2-b mercaptoethanol,
1mM DTT, 1mM MnCl2] using a French press. The
supernatant was incubated with Glutathion sepharose
4B (GE Healthcare) beads for 2h at room temperature.
The slurry was packed into a column and washed with
buffer B [50mM Tris–HCl (pH 7.5), 150mM NaCl,
1mM DTT, 0.1% 2-b mercaptoethanol, 1mM MnCl2].
The protein was eluted with buffer C [100mM Tris (pH
8), 10mM glutathione] and was dialyzed against buffer D
[50mM Tris (pH 7.5), 100mM NaCl, 1mM MnCl2,1m M
DTT, 0.1% 2-b mercaptoethanol and 10% glycerol]. The
proteins were stored at  80 C.
Dephosphorylation of puriﬁed Tra2-beta1-His6
Seven micrograms of puriﬁed recombinant
Tra2-beta1-His6 bound to Ni-NTA beads (Qiagen) was
phosphorylated in HeLa nuclear extract in the presence
of 5mCi [g
32P] ATP for 30min at 37 Ci n1   PNK
buffer. Beads were then washed with RIPA buffer and
aliquoted into tubes containing the indicated amounts of
PP1, C6 pyridinium ceramide, oxo-pyridinium, calyculin
A or ethanol as indicated in a 30ml volume containing
1  PP1 buffer. The dephosphorylation reactions were
incubated for 30min at 37 C and then boiled in
SDS-sample loading buffer. Samples were resolved by
SDS–PAGE and gels were coomassie stained and sub-
jected to phosphor imaging. The
32P signals and total
protein in coomassie stained gels were used to determine
the extent of Tra2-beta1 dephosphorylation.
Measurement of ceramides and sphingolipids by HPLC
tandem mass spectrometry
Ceramides were quantitated by HPLC electrospray ioniza-
tion tandem mass spectrometry using an ABI 4000 Q-Trap
hybrid linear ion trap triple quadrupole mass spectrometer
operated in multiple reaction monitoring (MRM) mode.
Ion currents associated with lipid species speciﬁc precursor
product ion pairs were determined as described by others
with minor adaptations (16). In brief, lipids were extracted
using acidiﬁed organic solvents (17), including 50pmol
C17 ceramide as a recovery standard. Ceramide molecular
species were resolved using a 3mm 100mm X-Terra
XDB-C8 column (3.5mm particle size, Waters, Milford,
MA, USA) and a gradient of methanol/water/formic
acid (61:39:0.5, v/v) containing 5mM ammonium formate
(solvent A) and acetonitrile/chloroform/water/formic acid
(90:10:0.5:0.5, v/v) with 5mM ammonium formate
(solvent B) at a ﬂow rate of 0.5ml/min.
The instrument was operated in positive mode with
optimal ion source settings determined empirically using
a set of synthetic ceramides. MRM transitions monitored
for the elution of ceramide molecular species were as
follows: m/z 510>264, 14:0-Cer; m/z 538:264, 16:0-Cer;
m/z 540:284, 16:0-DHCer; m/z 552:264, 17:0-Cer
(internal standard); m/z 564>264, 18:1-Cer; m/z
566>284, 18:1-DHCer; m/z 566>264, 18:0-Cer; m/z
568>284, 18:0-DHCer; m/z 594>264, 20:0-Cer;
m/z 596>284, 20:0-DHCer; m/z 624>284, 22:0-DHCer;
m/z 650>264, 24:1-Cer; m/z 652>284, 24:1-DHCer; m/z
652>264, 24:0-Cer; m/z 654>284, 24:0-DHCer;
m/z 680>264, 26:1-Cer; m/z 682>264, 26:0-Cer; m/z
708>264, 28:1-Cer; m/z 710>264, 28:0-Cer. Quan-
titation was accomplished by reference to standard
curves generated using synthetic standards obtained
from Avanti Polar Lipids (Alabaster AL) that were inde-
pendently determined by accurate mass measurements.
Measurements of C6 pyridinium ceramide and oxo-
pyridinium were accomplished using the extraction
method detailed above.
C6 pyridinium ceramide was separated using the
chromatographic methods used for natural ceramides
excepet that the MRM transitions monitored were m/z
476–379; 476–266 and 476–253. Precursor ion scanning
experiments indicated that the m/z 379 species was
derived by loss of the pyridinium group and the mz 266
and 253 species were derived by sequential loss of the
hydroxy groups from the resulting ion. Oxo-pyridinium
was separated by hydrophilic interaction chromatography
using a 4.6mm 100mm Luna HILIC column (3mM
particle size, Phenomenex, Torrance, CA, USA) with
monitoring of MRM transitions m/z 136>93, m/z
136>79, m/z 136>65, m/z 137>57.
Immunoprecipatation and western blots
For immunoprecipitation (IP) of PP1 isoforms, HEK293T
cells were grown to 70% conﬂuencency in 6-well plates
and transfected with 2mg of EGFP-C2 vectors expressing
PP1 alpha, PP1 beta, PP1 gamma or Tra2-beta1-RATA
[constructs described in (3)]. After 12–14h, cells were
treated with 0 and 10mM C6 pyridinium ceramide for
8h before preparation of cell extracts. Cells were
lysed for 30min at 4 C in 200ml of RIPA buffer
(20mM Na3PO4, 150mM NaCl, 1% NP-40, 1% sodium
deoxycholate, 5mM2-b mercaptoethanol, 0.1% SDS,
1mM EDTA, 1mM phenylmethylsulfonyl ﬂuoride,
5mg/ml of leupeptin, pepstatin A, antipain and aprotinin)
supplemented with 75U/ml Benzonase (Sigma-Aldrich).
RIPA-Rescue buffer (10mM sodium phosphate pH 7.2,
20mM NaCl, and freshly added 1mM dithiothreitol,
1mM phenylmethylsulfonyl ﬂuoride, and 20mg/ml apro-
tinin) was added to each reaction to a ﬁnal volume of
460ml and subsequently 40ml of pre-cleared 50% protein
A sepharose CL-4 bead suspension (GE HealthCare) were
added. The beads were washed once with 1ml RIPA
buffer and three times with RIPA-rescue buffer (10mM
sodium phosphate pH 7.2, 20mM NaCl, and freshly
added 1mM dithiothreitol, and 1mM phenylmethyl-
sulfonyl ﬂuoride) and were resuspended in a 60ml ﬁnal
volume. Thirty microliters of these beads were used for
western blotting while the remaining half was used for
the HPLC assay.
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C6 pyridinium ceramide (PyrCer) changes alternative
splicing of endogenous genes
Ceramides have previously been implicated in regulation
of splice site selection (7,8,18). However, the molecular
mechanism of ceramide action on pre-mRNA processing
is not clear, partly because ceramides are poorly soluble in
water. We therefore concentrated on C6 pyridinium
ceramide, a water-soluble ceramide analog which is cur-
rently being tested for the treatment of squamous cell car-
cinomas (19,20). To determine the inﬂuence of ceramide
action on alternative pre-mRNA splicing, we used a
medium-throughput RT-PCR screen (21) using RNA
from HEK293 cells treated with C6 pyridinium ceramide.
First, we used HEK293 cells in an MTT cytotoxicity
assay to determine a suitable concentration of PyrCer
for this screen. As a control, we used oxo-pyridinium, a
molecule that only differs from PyrCer by its propyl group
that replaces the short chain ceramide moiety. Our data
indicate that, at a 10mM concentration, there was
<5% cell death compared to higher concentrations of
PyrCer which lead to >80% cell death following a 24h
treatment (Supplementary Figure S2). In contrast,
increasing concentrations of oxo-pyridinium had no
effect on cell viability. These data also indicate that the
cytotoxicity of PyrCer is due to the ceramide group and
not due to the cationic pyridinium group which results in
its water solubility. Based on these studies, we treated cells
for 24h with 10mM PyrCer and analyzed the changes in
alternative splicing compared to oxo-pyridinium
treatment.
In total, 92 alternative splicing events were tested and
29 splicing events showed a signiﬁcant change in their
alternative splicing patterns. We validated these 29
events by performing RT-PCR with mRNA extracted
from HEK293 cells treated with or without 10mMC 6
pyridinium ceramide. From these, we selected ﬁve exons
with the most signiﬁcant changes for further analysis.
These exons were present in the DRF1, TIAF1, POL-b,
TAU and SYK pre-mRNAs. As shown in Figure 1, treat-
ment with 10mM PyrCer promoted both inclusion and
skipping of exons. As a negative control, we validated
the absence of a PyrCer effect on the pre-mRNAs of
CCNE1, ECT2, SHC1 and STM1 genes which showed
no change in the primary screen (Supplementary Figure
S3). Similar to other signal-dependent splicing systems
(22), exon inclusion differs around 10–20% between the
treated cells and controls. However, these differences are
statistically signiﬁcant, with P-values from the student’s
test <0.01.
The alternative exon usage in the DRF1 (Dbf4-related
factor 1) and POL-b (DNA polymerase beta) genes caused
a frameshift in the encoded pre-mRNAs. Alternative
splicing of the other exons in the TIAF1 (TGFB1-
induced antiapoptotic factor 1), TAU (microtubule
associated protein tau) and SYK (spleen tyrosine kinase)
transcripts retained their reading frames. The inclusion of
tau exon 10 has been shown previously to increase the
afﬁnity of the resulting tau isoform to microtubules and
aberrant exon 10 usage results in frontotemporal dementia
(23). These data suggest that a treatment with PyrCer
changes alternative splicing of several pre-mRNAs and
could have functional consequences for the cellular
proteome.
C6 pyridinium ceramide (PyrCer) changes alternative
splicing of exons in a heterologous context
To determine whether the sequence elements that respond
to PyrCer treatment are localized in the vicinity of the
regulated exons, we introduced the alternatively spliced
exons into reporter minigenes. We used a recently
developed recombination technique that introduces the
exon of interest between two constitutively spliced
insulin exons (14). Depending on the intron length, the
resulting reporter minigenes contained one to three
exons cloned between the constitutive insulin exons.
Their structures are schematically shown in Figure 2.
These reporter constructs were transfected into
HEK293 cells and the cells were subsequently treated
with C6 pyridinium ceramide. Total RNA was isolated
and analyzed using minigene-speciﬁc primers. In all
cases, we observed a C6 pyridinium ceramide-speciﬁc
change that was congruent with the changes observed
with the endogenous genes. However, the magnitude of
the effect on exon usage was larger in the transfection
studies, which was expected, as the reporter genes were
overexpressed. As an additional negative control, we
compared cells treated with the inactive Oxo-Pyr
(Supplementary Figure S2) with naı¨ve cells and found
no effect on alternative splicing of the DRF1, TIAF1,
POL-b, TAU and SYK pre-mRNAs (Supplementary
Figure S4). The data suggest that C6 pyridinium
ceramide-responsive sequences work in a heterologous
context and reside in the alternative exons or their imme-
diate ﬂanking exons and introns.
C6 pyridinium ceramide (PyrCer) inhibits PP1
It has been previously reported that ceramides promote
PP1 activity (13) and that exogenous D-(e)-C6-ceramide
causes SR-protein dephosphorylation (24). We therefore
tested whether the PyrCer has an inﬂuence on PP1 activity
using the classical p-nitrophenyl phosphate phosphatase
assay. An equimolar mixture of all three PP1 isoforms
puriﬁed from rabbit was used as the PP1 source. As
shown in Figure 3A, PyrCer blocks PP1 activity at
100mM concentration, when 0.1U PP1 are present. In
contrast, oxo-pyridinium that represents the water-soluble
moiety of PyrCer had no signiﬁcant effect. We used
calyculin A as a positive control for a PP1 inhibitor and
found that it inhibits PP1 activity at a 10nM concentra-
tion (Figure 3A and B). We next tested the inﬂuence of
PyrCer on the natural PP1 substrate phosphorylase phos-
phatase and again found an inhibition starting from
25mM (Figure 3C).
These data indicate that PyrCer inhibits PP1, although
at a >1000-fold higher concentration than established
phosphatase inhibitors like calyculin A or okadaic
acid. Collectively, these data show that unlike C6
ceramide which activates PP1 and promotes SR protein
4028 Nucleic Acids Research, 2012,Vol.40, No. 9Figure 1. C6 Ceramide changes alternative splicing patterns of several endogenous genes. RT-PCR analyses of RNA from cells treated for 24h with
C6 pyridinium ceramide. Two representative examples of untreated and cells treated with 10mM C6 pyridinium ceramide (PyrCer) are shown. The
exon–intron structure of the regulated genes is indicated schematically next to the ethidium bromide stained gels. Numbers indicate the length of the
exons. A statistical analysis of three independent experiments is shown on the right. The P values are (A–D) 0.0001 and (E) 0.001. The percent exon
inclusion was calculated by dividing the intensity of the band representing the regulated exon with the combined intensity of all bands. C is a
negative control without the reverse transcription. The regulated exons were: for DRF1 65nt; TIAF1 45nt; Pol-B: 58nt; tau: 93nt; SYK: 69nt and
are indicated in gray. Primers are indicated by arrows.
Nucleic Acids Research,2012, Vol.40, No. 9 4029Figure 2. Reporter gene constructs recapitulate the effect of C6 pyridinium ceramide. The alternative exons regulated by C6 pyridinium phosphate
were cloned between two constitutively spliced insulin exons into a heterologous splice reporter construct. One microgram of the constructs was
transfected into HEK293 cells and the cells were treated with PyrCer for 24h. Representative semi-quantitative RT-PCR analysis is shown. The
statistical evaluation is shown on the right and was performed as described for Figure 1.
4030 Nucleic Acids Research, 2012,Vol.40, No. 9dephosphorylation (13) its water-soluble pyridinium
analog, C6 pyridinium ceramide, inhibits PP1 activity.
C6 pyridinium ceramide treatment changes the
phosphorylation of several splicing factors in vitro
Numerous nuclear proteins contain putative PP1 binding
sites, and we recently showed that the splicing factors
SF2/ASF, Tra2-beta1 and SRp30c (also called SRSF9)
bind directly to PP1 using an evolutionarily conserved
RVxF motif located in their RRMs (3). PSF/SFPQ is
involved in several nuclear processes. It acts early in
spliceosome assembly, is involved in transcriptional regu-
lation and could play a role in homologous DNA recom-
bination (26–28). Importantly, PSF/SFPQ contains a PP1
binding site in its RRM, which regulates its ability
Figure 3. C6 pyridinium ceramide inhibits protein phosphatase-1. (A) An equimolar mixture of PP1 isoforms (alpha, beta and gamma) was
incubated with the concentrations of C6 pyrimidinim ceramide indicated and the activity on p-nitrophenylphosphate was determined.
1-(2-Oxopropyl) pyridinium was used as a negative control. (B) The effect on the PP1/PP2A inhibitor calyculin A is shown for comparison.
(C) PyrCer effect on PP1 dephosphorylating phosphorylase phosphatase. (D) PyrCer effect on the phophorylation of splicing factors. HeLa
nuclear extract was incubated with [g-
32P] ATP with or without 10mM PyrCer and the proteins indicated were immunoprecipated. The top lanes
(
32P) show the signal from overnight autoradiography. The signal form western blot using the antisera employed in immunorecipitations are shown
below. Tra2-beta1 and PSF migrate as doublet in western blots, which is due to different phosphorylation states (24). The numbers indicate the
molecular weights. (E) Effect of 10mM PyrCer on PP1-mediated dephosphorylation of puriﬁed Tra2-beta1 in vitro.
Nucleic Acids Research,2012, Vol.40, No. 9 4031to change alternative splicing (3,29,30). To determine
whether PyrCer inﬂuences the phosphorylation of other
nuclear proteins involved in splicing, we tested its effect
on a splicing competent HeLa nuclear extract. We
incubated HeLa nuclear extract with 4mCi [g-
32P] ATP
in the presence or absence of 10mM PyrCer and then
subjected the reactions to SDS–PAGE. Proteins with a
difference in phosphorylation signal were determined by
autoradiography. The differentially phosphorylated bands
were then identiﬁed by mass-spectrometry.
We next validated candidate genes by immunopre-
cipitation from extracts incubated with [g-
32P] ATP prior
to the addition of 10mM C6 pyridinium ceramide. The
phosphorylation of the immunoprecipated proteins was
detected by autoradioagraphy and their general abun-
dance was determined by by western blot. As shown in
Figure 3D, PyrCer treatment increases the phosphoryl-
ation of SF2/ASF, Tra2-beta1, PSF/SFPQ, UAP56 and
SAP155, but does not change overall abundance of these
proteins. Again, this effect is opposite of the water-soluble
C6-ceramide that promotes SF2/ASF dephosphorylation
(24).
We previously showed that PP1 dephosphorylated
Tra2-beta1 by binding to its RRM (3). As PyrCer in-
hibited Tra2-beta1 dephosphorylation in nuclear
extracts, we tested if it could inhibit PP1-mediated dephos-
phorylation of the splicing factor when using recombinant
proteins. His6-tagged Tra2-beta1 puriﬁed from insect cells
was
32P-labeled and treated with 10mM C6 pyridinium
ceramide or 10nM Okadaic acid in the presence or
absence of 0.2U of PP1. As expected, labeled
Tra2-beta1 (Figure 3E, lane 1) was dephosphorylated by
PP1 (Figure 3E, lane 2) but the presence of 10mMC 6
pyridinium ceramide inhibited the dephosphorylation of
Tra2-beta1 by PP1 (Figure 3E, lane 3), similar to
okadaic acid (Figure 3D, lane 4). Thus, PyrCer directly
interferes with the dephosphorylation of a splicing factor
by PP1.
Together, these data suggest that PyrCer treatment
increased the phosphorylation of several splicing factors,
which is likely caused by blocking PP1 activity. This effect
is the opposite of the water-insoluble natural and short
chain ceramides.
C6 Pyridinium Ceramide binds directly to PP1 in vivo
The inhibition of PP1 by PyrCer suggests that the two
molecules interact with each other. To explore this inter-
action in vivo, we developed a mass-spectrometric assay
for PyrCer detection. In brief, cells were treated with
pyridinium ceramide for 24h to allow PyrCer and PP1
to interact in vivo. Next, cells were washed and lysed,
PP1-bound lipids were isolated with antibodies against
PP1 and lipids were extracted from immune-complexes
with chloroform, separated with HPLC and detected by
ion trap triple quadrupole mass spectrometry
(Supplementary Figure S5A). This method gives a linear
response to PyrCer as shown in Supplementary Figure
S5B and S5C. To test whether C6 ceramide binds to PP1
in vivo, we immunoprecipitated endogenous PP1 from cells
that were treated with with or without 10mM PyrCer using
a pan-PP1 antibody (Figure 4A and B). The ceramide sig-
nal obtained from the mass-spectrometry was normalized
to the amount of PP1 present in the immunoprecipitations
(Figure 4B).
We found that that PyrCer associates with PP1 in vivo.
In addition, we performed a similar experiment with
EGFP-tagged PP1 isoforms that were transfected into
cells (Figure 4C). We immunoprecipitated the PP1
isoforms alpha and gamma using an antiserum against
the GFP tag. As shown in Figure 4C, both isoforms
bound PyrCer about equally. This interaction appears to
be speciﬁc, as we could not detect C6 ceramide in
immunoprecipitates of Tra2-beta1-RATA, a Tra2-beta
mutant that does not interact with PP1 (3) (Figure 4C).
As a further internal control, we analyzed the presence of
endogenous C18 ceramide in the immunoprecipitates. As
Figure 4. C6 pyridinium ceramide binds to protein phosphatase-1
in vivo. (A) Detection of PyrCer and C18 ceramide bound to PP1.
HEK293 cells were treated with 0 and 10mM C6 ceramide for 14h
and PP1 was isolated by immunoprecipitation with a pan-PP1
antibody. From the immunoprecipitates, bound lipids were extracted
with chloroform and analyzed by mass-spectrometry. The
mass-spectrometry signal was normalized to the amount of immunopre-
cipitated PP1, which was detected by western blot. The antiserum pre-
cipitates the catalytic subunit of PP1. (B) Detection of PyrCer bound to
PP1 variants. (C) EGFP-tagged constructs expressing PP1 gamma, PP1
alpha, Tra2-beta1-RATA were transfected into HEK293 cells and
immunoprecipitated with an anti EGFP antiserum. PyrCer bound to
the immunoprecipitates was determined by mass-spectrometry and
normalized to the signal obtained by western blot using anti EGFP.
4032 Nucleic Acids Research, 2012,Vol.40, No. 9shown in Figure 4A, C18 ceramide is associated with PP1
in untreated cells. However, the amount of C18 ceramide
is reduced upon PyrCer addition, suggesting that both
compounds might compete for the same binding site.
Finally, we determined whether PyrCer is taken up by
cells or exerts its action by stimulating signal transduction
cascades emenating from the cell membrane. We added
10mM PyrCer to the cell medium and determined its intra-
cellular distribution by cell fractionation. As shown in
Supplemental Figure S6, about half of the lipid is
accumulated in the cells after 24h, with 40% in the
cytosol and 10% in nuclear fractions. This argues that
PyrCer can directly interact with cellular PP1 that is
present in both the cytosol and nucleus.
In summary, these data show that cells take up C6
pyridinium ceramide, where it binds directly to PP1 and
inhibits the phosphatase.
C6 ceramide responsive exons have common features
At a concentration of 10mM, PyrCer changes alternative
splicing of several exons in vivo (Figures 1 and 2). This
could indicate that protein complexes forming around
certain exons are more sensitive to PyrCer action and
are changed at 10mM concentration, which results in the
preferential usage of another splicing pathway. To deter-
mine what features these exons have in common, we
performed component analysis of the exons. All
ceramide responsive cassette exons that we identiﬁed are
shorter than the mammalian consensus length for cassette
exons, which is around 150nt. The mean length of the
ceramide-responsive exons is 66nt, with a SD of 20nt
(Supplemental Figure S7B). It is therefore likely that
these exons depend on enhancer sequences to overcome
their short length.
In order to determine common elements of PyrCer re-
sponsive exons, we performed MEME (Multiple
Expectation matrices for Motif Elicitation) analysis of
the sequences (31). We found that each PyrCer-regulated
exon contains a GAAR and a CAAR motif (Supplemental
Figure S7A). In addition, all exons contained SF2/ASF
binding motifs predicted by ESE ﬁnder (32). The next
common feature shared by all ceramide-responsive exons
is suboptimal splice sites. The combined 30 and 50 splice
sites ﬂanking PyrCer-responsive exons have an average
splice-site-strength score of 7.5, whereas the control con-
stitutive exons have a score of 15, when calculated by a lod
score algorithm based on mammalian splice sites (33)
(Supplemental Figure S7C).
We next asked whether some of the regulated exons
bind directly to PSF/SFPQ, SF2/ASF and Tra2-beta1,
proteins that are dephosphorylated by PP1 and predicted
to bind to PyrCer-reponsive exons. We puriﬁed
PSF/SFPQ, SF2/ASF and Tra2-beta1 from bacteria and
performed in vitro gel retardation assays using probes cor-
responding to the parts of POL-B and TIAF1 exons that
contain the GAAR and CAAR motifs. As controls, we
used arteﬁcial oligonucleotides where these motifs were
deleted. As shown in Figure 5, all three proteins bound
to TIAF1 exon sequences. However Tra2-beta1 did not
bind to the POL-B-exon RNA. This was surprising,
since the exon containes one AGAA binding motif that
is the high afﬁnity binding site for Tra2-beta1 (34). This
suggests that an unknown sequence context contributes to
Tra2-beta1 binding. The binding of Tra2-beta1, SF2/ASF
and PSF to tau exon 10 has been reported earlier (35–37).
We conclude that C6 pyridinium-dependent alternative
exons have suboptimal length, suboptimal splice sites and
contain binding sites characteristic for splicing enhancers.
It is therefore likely that their regulation is dependent
on regulatory protein complexes that form on the
pre-mRNA.
Splicing regulators with a PP1 binding site inﬂuence the
regulation of C6 pyridinium ceramide responsive exons
We found that PyrCer treatment of HeLa nuclear extract
caused an increase in the levels of phosphorylation of
splicing factors PSF/SFPQ, SF2/ASF and Tra2-beta1
(Figure 3D). All these splicing factors are known to
interact with PP1 (3). Therefore, we investigated the pos-
sibility that these splicing factors could effect splicing of
the PyrCer-regulated exons.
As shown in Figure 6, the usage of all exons is changed
by PSF. With the exception of the DRF1 pre-mRNA, PSF
promotes exon skipping or inclusion of the tested reporter
genes in a similar way as C6 pyridinium ceramide. SELEX
experiments showed that PSF binds to sequences contain-
ing GAA-motifs (38) that are enriched in C6 pyridinium
ceramide-responsive exons (Supplemental Figure S7A).
Bioinformatic analysis using ESE ﬁnder (32)
indicates SF2/ASF binding sites in the regulated exons.
Furthermore, all exons with the exception of DRF1
contain the high afﬁnity Tra2-beta1 binding site AGAA.
However, DRF1 contains the lower afﬁnity Tra2-beta1
site TGAA. In vitro, Tra2-beta1 binds to AGAA and
TGAA with 2.2 and 4.5mM afﬁnity, respectively (34).
We therefore analyzed the ceramide-responsive minigenes
in co-transfection experiments together with constructs
expressing SF2/ASF and Tra2-beta1.
As shown in Figure 7, all exons respond to SF2/ASF
and Tra2-beta1, which supports the bioinformatic predic-
tion. It is noticeable that SF2/ASF promotes exon
skipping in most cases, and Tra2-beta1 promotes
skipping of an exon in the TIAF1 pre-mRNA, which is
in contrast to their usual function as splicing activators.
This unusual effect of SF2/ASF on tau exon 10 has been
previously observed (39). The effect of tra2-beta1 on the
POL-B alternative exons was much weaker than on
TIAF1, which correlates with the strong binding of
tra2-beta1 in vitro to the TIAF1 pre-mRNA and our in-
ability to detect binding of tra2-beta1 to POL-B
(Figure 5). Both SF2/ASF and Tra2-beta1 are direct sub-
strates for PP1 and PP1-mediated dephosphorylation that
promotes their interaction (3) and it is possible that
PyrCer affects exons that are dependent on both factors.
These data indicate that ceramide responsive alternative
exons are dependent on splicing regulatory proteins that
carry PP1 binding sites. The exons show the strongest
response to PSF, suggesting that this factor is central to
mediating the signaling between PyrCer and the splicing
machinery.
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Role of lipids in RNA metabolism
Lipids have been long known for their role as signaling
molecules that are important for human health. Their
best-understood mode of action is the regulation of
protein phosphorylation by modulating the activity of
kinases and phosphatases (40). However, there is
emerging evidence that lipids directly interfere with
RNA metabolism. For example, high levels of palmitaic
acid are toxic for cells, which is mediated through an inter-
action with snoRNAs in the cytosol, where snoRNAs are
normally not detectable (41). Similar to our ﬁndings,
different lipids show various degrees of toxcicity and
RNA association. RNAs were shown to directly bind to
membranes where it associates with liquid-ordered rafts
(42) and RNA induced silencing complexes (RISC) are
associated with endosomal membranes (43,44), suggesting
that lipid composition regulates RNA processing
complexes. The function of the lipids could be structural
by providing scaffolds for protein and RNA assembly as
well as catalytic by interfering with the activity of RNA
processing enzymes, which was tested here.
In contrast to long-chain ceramides, C6 pyridinium
ceramide blocks endogenous protein phosphatase-1 activity
Previously, it was found that short chain D-erythro-C6
ceramide (24) and long-chain D-erythro-C18-ceramide
activate PP1 (13) and cause a decrease in SR-protein
Figure 5. PSF, SF2/ASF and Tra2-beta1 bind to motifs enriched in PyrCer dependent exons. (A) Gel retardation assay with TIAF1 and control
probes. (B) Gel retardation assay with POL-B and control probes. (C) Sequence of the RNA probes. The GAAR motif is underlined, the CAAG
motif is underlined with zigzag. The SF2/ASF site is indicated by a dotted superscript. The concentration of all oligonucleotides was 0.4mM in all
reactions in a total volume of 10ml. The protein concentrations for Tra2-beta1 were 0, 2.4, 3.6, 4.8 and 7.2mM in lanes 1–5, respectively. The
concentrations for PSF/SFPQ were 0, 0.5, 1.1, 2.1 and 3.2mM in lanes 1–5, respectively. The concentration for SF2/ASF was 0, 1.1, 2.8, 4.0 and
5.7mM and in lanes 1–5, respectively.
4034 Nucleic Acids Research, 2012,Vol.40, No. 9Figure 6. PSF regulates ceramide responsive exons. The reporter genes shown in Figure 2 were co-transfected with a construct expressing PSF
(A–E). The statistical analysis is shown on the right: n=4, P=0.0001, 0.01, 0.009, 0.024, 0.013 for DRF1, TIAF1, POL-B, tau and SYK. F shows
the increase of EGFP-PSF protein upon overexpression, detected by an antibody against GFP. Note that no PyrCer was added in these experiments.
Nucleic Acids Research,2012, Vol.40, No. 9 4035Figure 7. Splicing regulators with a PP1 binding site regulate ceramide responsive exons. The reporter genes shown in Figure 2 were co-transfected
with constructs expressing SF2/ASF or Tra2-beta1. RNA was isolated and analyzed by RT-PCR (A–E). The statistical analysis of at least three
independent experiments is shown on the right. Note that no PyrCer was added in these experiments. (F) Detection of GFP-SF2/ASF and GFP-
Tra2-beta1 by Western Blot analysis.
4036 Nucleic Acids Research, 2012,Vol.40, No. 9phosphorylation. As water-soluble ceramides are used as
anti-cancer agents, we tested the effect of the water-soluble
derivative PyrCer on PP1 activity. Surprisingly we found
that PyrCer inhibits the phosphatase, both when using
recombinant proteins and nuclear extract. In agreement
with an inhibition of PP1, PyrCer causes an increase of
phosphorylation of SF2/ASF, the opposite of its natural
derivatives, and the short non-cationic D-erythro-C6
ceramide. Puriﬁed PP1 is inhibited starting at 50mM,
whereas proteins in nuclear extract are inﬂuenced at
10mM C6 pyridinium ceramide. As PP1 is located in
protein complexes, it is likely that allosteric effects that
interfere with these complexes play a role in blocking the
dephosphorylation of splicing factors. We showed that
PyrCer is taken up by the cells and found it in
PP1 immunprecipitates, which indicates a direct inter-
action with PP1, rather than a signal that is
mediated through other pathways. These differences in
PP1 inhibitions have functional consequences, as PyrCer
and related short chain ceramides have different effects on
alternative splicing: D-e-C6-ceramide changes bcl-x alter-
native splicing (7), whereas PyrCer has no effect
(Sumanasekera, C. et al., unpublished data).
The ﬁnding that chemically related lipids have oppo-
sing effects on PP1 activity and splicing factor phosphor-
ylation indicates that the cell could use lipid modiﬁcation
to control the phosphorylation of PP1 targets, among
them splicing factors. Such lipid modiﬁcations have been
well documented for the glycerophospholipids, where the
electric charge of the water-soluble group is subject to
modiﬁcation, as exempliﬁed by the conversion of phos-
photidylinositols to negatively charged phosphoinositides
that have distinct signaling properties (45).
C6 pyridinium ceramide inﬂuences the phosphorylation
of splicing factors
We used a mass-spectrometry approach to identify
splicing factors that change their phosphorylation due to
PyrCer treatment. The rationale was that both PP1 and
splicing factor kinases are present in nuclear extract,
where they are required for splicing activity (46,47). The
screen resulted in the identiﬁcation of ﬁve proteins that
had an increase in their phosphorylation upon PyrCer
treatment: PSF/SFPQ, SF2/ASF, Tra2-beta1, UAP56
and SAP155. Whereas the ﬁrst three proteins are known
to interact with PP1 and contain an evolutionary
conserved binding site for PP1 in their RRMs, UAP56
and SAP155 are not known to directly bind to PP1.
However, it was shown that PP1 is directed to SAP155
via an intermediate protein, NIPP-1 (48). It is possible
that PyrCer interferes with the PP1-mediated
dephosphorylation of SAP155 by blocking catalysis in a
NIPP-1/PP1/SAP155 complex.
Using recombinant proteins, we tested the effect on
PyrCer on the dephosphorylation of Tra2-beta1 by
PP1. We found the PyrCer blocks the dephosphorylation
in this system, indicating a direct inﬂuence on the
phosphatase-substrate complex. Surprisingly, we did not
detect a PyrCer-mediated change of phosphorylation in
RNA processing proteins that contain a PP1 binding
motif in their RRM, such as SRp30c, RBM15b, SFRS11
and ROD1. In in vitro assays, SR proteins are often very
similar, whereas in vivo analysis shows that they have
discrete functions (49). Our ﬁndings indicate that chem-
ically related lipids can have opposing effects on the phos-
phorylation and activity of SR proteins, which could
contribute to their physiological regulation.
The C6 pyridinium ceramide signal is transduced
by PSF/SFPQ, not only SR proteins
A medium-throughput PCR screen revealed several alter-
native splicing events that are regulated by C6 pyridinium
ceramide. All exons identiﬁed were cassette exons that
were signiﬁcantly shorter than constitutive exons and
were surrounded by weak splice sites. A search for
motifs revealed the occurrence of GAAR and CAAR
motifs in each exon. Each motif is expected to be
present once in every 128nt by chance, and should occur
2.5 times when all exons are considered. In the regulated
exons there are 7 GAAR and 11 CAAG motifs, suggesting
that these motifs are 7-fold enriched in C6 pyridinium
ceramide-dependent exons. The motifs overlap with
predicted PSF, SF2/ASF and Tra2-beta1 binding sites.
The role of these proteins in regulating ceramide-
responsive exons was tested by cotransfection experiments
and direct protein binding and PSF showed the strongest
effect. This was surprising, as PSF was not known to be
regulated by ceramide and is not an SR protein, a protein
class previously shown to be regulated by ceramides (18).
It was also unexpected that SF2/ASF promoted mostly
exon skipping, which is another unusual feature of PyrCer
dependent exons. A possible mechanism could be a
recruitment of PP1 by SF2/ASF to the pre-mRNA. The
overexpression of SF2/ASF could recruit too much PP1 to
the pre-mRNA, which would result in aberrant
protein:RNA complexes. In agreement with this model,
we observed skipping of C6-ceramide dependent exons
when PP1 gamma was overexpressed in transfection
studies (data not shown).
The stronger effect of PSF on PyrCer dependent exons
could indicate that different lipids prefer distinct splicing
factors as targets, suggesting that lipid composition could
regulate alternative splice site selection in vivo.
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